https://www.selleckchem.com/pr....oducts/omaveloxolone
Aim To assess the patterns of genetic testing for homologous recombination repair mutations in patients with metastatic castration-resistant prostate cancer (mCRPC) pre-PARP inhibitors approval. Patients methods mCRPC patients were selected in an oncology electronic medical records database. Patterns and predictors of testing for ATM, BRCA1/2, CDK12, PALB2 and FANCA gene alterations were assessed. Results Of 5213 mCRPC patients, 674 (13%) had a documented genetic test. The number of tested patients increased from 1 i
Like
Comment
Share
